COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04289220
Recruitment Status : Not yet recruiting
First Posted : February 28, 2020
Last Update Posted : February 28, 2020
Information provided by (Responsible Party):
Yan'an Affiliated Hospital of Kunming Medical University

Brief Summary:
Our previous study demonstrated that anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells have strong tumor-killing activity in vitro and therapeutic effects in cell line-derived xenograft models, and no obvious side effects such as neurotoxicity and cytokine storm occurred. Therefore, we want to evaluate the safety and clinical effect of anti-CD19 CAR-T cells in clinical trials.

Condition or disease Intervention/treatment Phase
B Cell Lymphoma B-cell Acute Lymphoblastic Leukemia Biological: Anti-CD19 CAR-T Cells Injection Phase 1

Detailed Description:

Using piggyBac transposon/transposase system to deliver genes into primary human T cells - example expression of CD19 CAR.CARs specific to the human CD19 antigen were used. All CARs contained the scFv against human CD19 (clone FMC-63), The third BBz CD28z CAR consisted of the scFv linked to the intracellular domains of CD28, 4-1BB and CD3z through a CD28 transmembrane domain;

Subjects with relapsed/refractory CD19-positive B-cell Lymphoma or B-ALL can participate if all eligibility criteria are met. All patients received chemotherapy with fludarabine and cyclophosphamide before the infusion of anti-CD19 CAR-T cells.. After the infusion, subjects will accept follow-up for side effects and effect of anti-CD19 CAR-T cells.

Follow-up :

Safety and adverse events (safety and tolerability of anti-CD19 CAR-T cell therapy within 14 days): The number and severity of adverse events, an evaluation of their association with the anti-CD19 CAR-T cell treatment, and the outcome of the adverse events. Possible adverse events include cytokine release syndrome, hypotension, reversible neurotoxicity, hypogammaglobulinemia, etc. CT was used to evaluate B-lymphoma lesions. B-ALL bone marrow samples were collected by bone marrow aspiration to assess minimal residual disease. Flow cytometry was used to detect proportion of T cells, B cells, and NK cells in the blood, and expression of CD3, CD4, CD8, anti-CD19 CAR to determine the effect of anti-CD19 CAR-T treatment. Plasma levels of the cytokines IFN-gamma, TNF-α, IL-2, GM-CSF, IL-10, and IL-6 were also determined.

Data analysis:

Overall survival and progress free survival were determined by the Kaplan-Meier method, using all enrolled patients to determine overall survival.

Study procedures may be performed while hospitalized.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Clinical Trial of Anti-CD19 Chimeric Antigen Receptor in PiggyBac Transposon-Engineered T Cells for the Treatment of Patients With Relapsed/Refractory/High-risk B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia
Estimated Study Start Date : March 15, 2020
Estimated Primary Completion Date : March 15, 2023
Estimated Study Completion Date : September 15, 2023

Arm Intervention/treatment
Experimental: Anti-CD19 CAR-T Cells Injection
Anti-CD19 CAR-T Cells Injection, Dosage form:injection Dosage:1-2.5x10^6/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
Biological: Anti-CD19 CAR-T Cells Injection
Dosage form:injection Dosage:1-2.5x10^6 cells/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time

Primary Outcome Measures :
  1. Grade and number of cytokine release syndrome and neurotoxic effects in participants receiving treatment [ Time Frame: 14 day ]
    Anti-CD19 CAR-T cells growing use requires further education/training and prompt management of safety and tolerability.

  2. Persistence of anti-CD19 CAR-T cells in participants [ Time Frame: 1 year ]
    Copies numbers of CAR in peripheral blood (PB)

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 3 years ]
    For all subjects, overall survival refers to the period from being included in the test group to death caused by any reason

  2. Progress Free Survival [ Time Frame: 3 years ]
    Progression-free survival refers to the period between the start of treatment for participants and the observation of disease progression or death for any reason.

  3. Duration of Response after administration [ Time Frame: 3 years ]
    Duration of Response after administration

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients or their legal guardians voluntarily participate and sign the Informed Consent Document;
  2. Male or female patients aged 18 to 70 years (inclusive);
  3. Pathologically and histologically confirmed CD19 + B cell tumors; Patients currently have no effective treatment options, such as chemotherapy or relapse after hematopoietic stem cell transplantation; Or patients voluntarily choose transfusion of anti-CD19 CAR-T cells as the first treatment program;
  4. B-cell tumors / lymphomas and B-cell acute lymphoblastic leukemia include the following four types:1) B-cell acute lymphoblastic leukemia;2) Indolent B-cell lymphomas;3) Aggressive B-cell lymphoma; 4) Multiple myeloma;
  5. Subjects:

(1) Residual lesions remain after treatment and Not suitable for Hematopoietic stem cell transplantation (auto/allo-HSCT); (2) Relapse after Complement receptor 1 (CR1) and unsuitable for HSCT; (3) Patients with high risk factors; (4) Relapse or no remission after hematopoietic stem cell transplantation or cell immunotherapy.

6. Have measurable or evaluable tumor foci;

7. Liver, kidney and cardiopulmonary functions meet the following requirements:

1) Serum glutamic pyruvic transaminase (ALT) and serum glutamic oxaloacetic transaminase (AST) <3 ×upper limit of normal (ULN);2) Total bilirubin ≤34.2μmol/L;3) Serum creatinine<220μmol/L;4) Baseline oxygen saturation≥95%;5) Left ventricular ejection fraction(LVEF)≥40%.

8. Subjects who did not receive Chemotherapy, Radiotherapy, Immunotherapy (immunosuppressive drugs) or other treatment within 4 weeks prior to enrollment; Relevant toxicity≤1 grade before enrollment (except for low toxicity such as hair loss);

9. Peripheral superficial venous blood flow is smooth, which can meet the needs of intravenous drip;

10. Clinical performance status of eastern cancer cooperation group (ECOG) score ≤2,Expected survival≥3 months;

Exclusion Criteria:

  1. Pregnant (urine/blood pregnancy test positive) or lactating women;
  2. Planned pregnancy during treatment or within 1 year after treatment, or a male subject whose partner plans pregnancy within 1 year of their cell transfusion;
  3. Patients cannot guarantee effective contraception (condom or contraceptives, etc.) within 1 year after enrollment;
  4. Active or uncontrollable infection within four weeks prior to enrollment;
  5. Patients with active hepatitis B/C;
  6. HIV-infected patients;
  7. Severe autoimmune or immunodeficiency disorders;
  8. Patients are allergic to macromolecule drugs such as antigens or cytokines;
  9. Subjects participated in other clinical trials within 6 weeks before enrollment;
  10. Systematic use of hormones within 4 weeks prior to enrollment (except for inhaled hormones);
  11. Mental illness;
  12. Drug abuse/addiction;
  13. The investigators consider other conditions unsuitable for enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04289220

Layout table for location contacts
Contact: Zongliu Hou 86-0871-63211157

Layout table for location information
China, Yunnan
Kunming Yan'an Hospital
Kunming, Yunnan, China, 650000
Contact: Lin Li   
Sponsors and Collaborators
Yan'an Affiliated Hospital of Kunming Medical University
Layout table for investigator information
Study Director: Zongliu Hou Kunming Yan'an Hospital
Layout table for additonal information
Responsible Party: Yan'an Affiliated Hospital of Kunming Medical University Identifier: NCT04289220    
Other Study ID Numbers: 2019-1-N-25318000002027
First Posted: February 28, 2020    Key Record Dates
Last Update Posted: February 28, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin